Powered by QBIView · Quadros Bio Investment View
QBIView Rapid
A 30-question diagnostic of biological product readiness, scored against the seven QBIView dimensions. Instant online report with a Go, Conditional, or No-Go signal.
Secure checkout via Stripe. Email receipt and assessment link delivered immediately on payment.
Preview the Report
One page of charts. Four to five pages of expert diagnosis.
Your QBIView Rapid report opens with a one-page visual dashboard, then continues with a detailed written diagnosis written for your executive team or investors.
Page 1 of your report — example data. The remaining four to five pages contain your written diagnosis.
Inside the report
- →Overall readiness score (0–100) with a Go, Conditional, or No-Go signal
- →Score-by-department breakdown across R&D, Operations, Finance, Commercial, People, and Compliance
- →Risk radar and priority matrix — visual at-a-glance for any reader
- →Top three priority risks named, scored, and explained
- →Relative strengths to build on (the levers already in your favour)
- →1200–1600 word written diagnosis: Executive Diagnosis, Top 3 Readiness Gaps, Strengths to Build On, Recommended Next Steps, Advisory Notes
- →Downloadable as a clean four to five page PDF for IC packets, board meetings, or investor decks
How to use the suggestions
The Recommended Next Steps section delivers four to five concrete, sequenced actions you can put on a 90-day plan. The Top 3 Readiness Gaps section names the specific bottlenecks holding the company back from being investor- or partner-ready. The Advisory Notes section is the perspective you would get from a senior scientific advisor in a one-hour consultation — captured in writing so you can share it with co-founders, investors, or your board without scheduling a call.
What You Receive
A two-page scored report, online, the moment you finish.
Instant scored report
A structured online report delivered the moment you complete the 30 questions. No waiting, no email turnaround.
Go / Conditional / No-Go signal
A clear first read on where the product or company stands and where to focus next.
Seven-pillar breakdown
Independent scoring across the seven QBIView readiness dimensions, so weaknesses do not hide behind strengths.
Confidential by default
Responses are used solely to generate your report. They are not shared, not sold, and not used for marketing without permission.
What we score
Seven independent readiness layers.
QBIView Rapid condenses the full QBIView framework into a short questionnaire that surfaces signal across all seven dimensions. Each layer is scored on its own so weaknesses do not hide behind strengths.
- 01Biological Validity
- 02Product Integrity
- 03Field Translation
- 04Regulatory Pathway
- 05Commercial Viability
- 06Organizational & IP Strength
- 07R&D and Governance
How It Works
Three steps, online, end to end.
01
Pay
Secure Stripe checkout in CAD. Card or supported wallet. Email receipt arrives immediately.
02
Answer the 30 questions
Eight to twelve minutes. No account required. Confidential responses used only to generate your report.
03
Get your scored report
Instant online report with seven-layer scoring and a Go, Conditional, or No-Go signal you can act on.
Before you begin: please read
Not investment advice. QBIView Rapid is a scientific diagnostic tool for informational purposes only. It does not constitute investment advice, financial advice, or a securities recommendation. Results reflect Quadros Bio Inc.'s independent technical analysis and are not a guarantee of product performance, regulatory approval, or commercial success. All investment decisions should be made with qualified professional advisors.
By purchasing and submitting this assessment, you confirm that you have read and agree to the QBIView Terms of Use and the QBIView Privacy Policy, and that the information you provide is accurate to the best of your knowledge.
Ready to run the assessment?
CAD $99 or R$ 390. Pay, answer, get your scored report. Done.
Secure checkout via Stripe. Email receipt and assessment link delivered immediately on payment.
Confidential by default. Not sold. Not published. Not shared without permission.